Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis B
US11168055B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2018 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | Jul 13, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F7/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are an endocyclic thiamidinoamide-arylamide compound and a pharmaceutical composition comprising the compound described above, and the use of the compound or pharmaceutical composition in the treatment of hepatitis B. In particular, disclosed is a compound that can be used as an HBV replication inhibitor and has the structure as shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.